Listen to this articleAs weight loss drugs become more popular, Nestlé Health Science wants to ensure that consumers taking the medication have comprehensive nutritional support.
The global leader in nutritional science announced in a June 25 press release that it is launching a platform to provide information to individuals working on weight management, including those undergoing GLP-1 therapy.
The subsidiary of Swiss food and beverage giant Nestle said the website offers nutritional information and product bundling options tailored to the needs of individuals, especially those taking medications such as Wegobee, Ozempic, Mounjaro and Ryversus.
Areas of focus for these products include muscle maintenance, gut health, micronutrient intake, hydration, skin and hair health and weight loss management.
Nestlé Health Science, with its global research and development centre in Bridgewater, offers a wide range of advanced, science-based nutrition solutions to consumers, patients and healthcare professionals.
The company’s portfolio includes Boost, Carnation Breakfast Essentials, Vital Proteins, Garden of Life, Nature’s Bounty, etc. Additionally, it offers pharmaceutical therapies to prevent, manage and treat gastrointestinal and metabolic related disorders.
Targeted Solutions
The new website also offers expert nutrition insights and a community platform for individuals to share experiences and support each other on their health journey. According to Nestlé Health Science, users can connect with nutrition coaches for any queries related to diet, lifestyle and supplements.
“The introduction of this new innovative tool marks an important step forward in the mission and focus of our business,” said Anna Mohr, CEO of Nestlé Health Science.
“With this offering, we reaffirm our commitment to enabling healthier living through targeted, personalized nutrition solutions. We are excited to continue redefining health and wellness solutions and improving the quality of life for people seeking effective weight management strategies,” commented Mohr.
While it is unclear how many Americans currently take GLP-1 drugs for weight loss, a Goldman Sachs study projects that up to 70 million people across the U.S. will try the drugs by 2028. As drug adoption expands, companies across multiple industries are expected to adapt to changing consumer behavior through product innovation and portfolio restructuring efforts.
But questions remain about what happens if patients take prescription drugs long-term, or how long they should continue to take drugs such as Ozempic and Wegovee, both made by Novo Nordisk Inc. The global pharmaceutical company has its U.S. headquarters in Plainsboro.
Last month, Secaucus-based The Vitamin Shoppe announced a telehealth service focused on weight management solutions. In addition to subscription plans for weight-loss medications, the platform includes resources to help patients make healthy lifestyle choices.
